Core Insights - Daré Bioscience, Inc. is focused on women's health and aims to bridge the gap between scientific advancements and real-world solutions, with significant developments expected in 2026 [2][27]. Business Highlights and Recent Developments - The company launched DARE to PLAY™, a topical sildenafil cream for women, which is the first of its kind with clinical data showing increased genital blood flow within 10 to 15 minutes and improvements in arousal, orgasm, and desire [3][4]. - DARE to RESTORE™ is a new brand of consumer health products aimed at supporting vaginal microbiome balance, with the first product, Flora Sync LF5™, expected to be available in Q2 2026 [4][6]. - DARE to RECLAIM™, a monthly bio-identical hormone therapy product, is targeting the compounded hormone therapy market, estimated at $2.5 to $4.5 billion, with availability expected in early 2027 [7][8]. - Ovaprene®, a non-hormonal contraceptive candidate, is currently in a Phase 3 clinical trial, with completion of enrollment anticipated in 2026 [9][10]. - DARE-HPV, an investigational therapeutic for high-risk HPV infections, is preparing to enter a Phase 2 clinical study with funding from ARPA-H [11][12]. Financial Results and Position - As of December 31, 2025, the company reported approximately $24.7 million in cash and cash equivalents, with working capital of about $3.4 million [16][36]. - In 2025, Daré raised approximately $20.8 million through equity offerings and received significant non-dilutive funding, allowing for the advancement of multiple programs [17][21]. - Operating expenses for 2025 were approximately $14.3 million, a decrease from $23.5 million in 2024, primarily due to lower R&D expenses and stock-based compensation [18][19]. Revenue Outlook - The company expects to begin recording product revenue from DARE to PLAY and Flora Sync LF5 in Q2 2026, with revenue from DARE to RECLAIM targeted for 2027 [23][20].

Core Viewpoint - Daré Bioscience is introducing DARE to PLAY™ Sildenafil Cream, a groundbreaking topical arousal cream specifically designed for women, aiming to address the long-ignored area of women's sexual health [1][5][21]. Product Overview - DARE to PLAY™ is the first clinically studied topical arousal cream for women, utilizing sildenafil, the same active ingredient found in Viagra, to enhance genital blood flow and improve arousal sensations [2][4][14]. - The cream is designed to be applied topically, providing localized effects within 10-15 minutes, unlike oral sildenafil [6][17]. Market Opportunity - Approximately 20 million women in the U.S. face challenges related to genital arousal, with no FDA-approved therapeutics currently available to address this need [17]. - The introduction of DARE to PLAY™ aims to fill this significant gap in the market, providing a science-backed solution for women's sexual health [5][21]. Clinical Evidence - DARE to PLAY™ has undergone clinical studies focused on female physiology and response, demonstrating its effectiveness in increasing genital blood flow and enhancing natural arousal sensations [4][19]. - The product is supported by peer-reviewed research published in reputable medical journals, ensuring its credibility and scientific rigor [19][21]. Regulatory and Manufacturing Aspects - DARE to PLAY™ will be available as a Section 503B compounded product, manufactured in compliance with current Good Manufacturing Practice (cGMP) regulations, ensuring quality and consistency [15][18]. - The company is pursuing FDA approval for its proprietary sildenafil cream formulation while providing earlier access to patients through the compounded product [15][19]. Company Mission and Vision - Daré Bioscience is dedicated to transforming women's sexual and reproductive health through innovative science, focusing on closing the gap between promising research and real-world solutions [21][22]. - The company emphasizes the need for increased investment and attention in women's health, advocating for evidence-based solutions that have been historically underfunded and underserved [5][22].

Core Insights - Daré Bioscience has received a revised Notice of Award from the NIH for approximately $2 million in funding for its investigational product DARE-PTB1, aimed at preventing preterm birth, a condition with no FDA-approved treatment options [1][4] - The funding period has been extended through November 2026, allowing the company to continue its clinical studies [1][4] - DARE-PTB1 is designed to deliver bio-identical progesterone via an intravaginal ring for up to 14 days, targeting at-risk women [2] Funding and Development - The total NIH funding for the DARE-PTB1 project is approximately $2 million, with the latest tranche of about $1 million extended through November 30, 2026 [1][4] - The project began on December 12, 2023, and supports a Phase 1 comparative pharmacokinetics clinical study [4] Company Strategy - Daré Bioscience focuses on addressing unmet needs in women's health through a differentiated pipeline, leveraging non-dilutive grant funding to advance its projects [1][6] - The company aims to provide innovative solutions across various women's health issues, including preterm birth, HPV-related diseases, and sexual health [3][6] Product Insights - DARE-PTB1 benefits from insights gained from the DARE-HRT1 program, which showed positive results in earlier clinical trials using the same IVR technology [3] - The company is also developing other products, such as DARE to PLAY™ Sildenafil Cream, which targets sexual health needs in women [7][8] Market Context - Women's health is often underfunded, and Daré's strategic partnerships, including with the NIH, provide a competitive advantage in advancing its pipeline [6][7] - The company is committed to transforming women's sexual and reproductive health through innovative science and addressing significant gaps in care [17][18]

Core Insights - Daré Bioscience has launched DARE to PLAY™ Sildenafil Cream, a first-of-its-kind topical arousal cream for women, now available in all 50 states, aimed at enhancing female sexual health and addressing a significant gender gap in medical solutions [1][2][15]. Product Overview - DARE to PLAY™ is a non-hormonal topical cream that increases genital blood flow within 10-15 minutes and improves arousal sensations based on clinical studies [1][12]. - The cream utilizes sildenafil, the same active ingredient found in Viagra®, but is specifically formulated for women, providing a new evidence-based tool for sexual health [12][13]. Telehealth and Accessibility - Telehealth consultations for obtaining prescriptions for DARE to PLAY™ are now available nationwide, allowing women to connect with healthcare providers conveniently [2][3]. - The DARE Health Hub, powered by Medvantx Pharmacy, facilitates secure online consultations, making it easier for women to access the product without in-person visits [3][4]. Market Opportunity - Approximately 20 million women in the U.S. face challenges related to genital arousal, with no FDA-approved therapeutics currently available to address this need, highlighting a significant market opportunity for DARE to PLAY™ [15]. - The product is manufactured in a 503B outsourcing facility, ensuring compliance with current Good Manufacturing Practice (cGMP) regulations, which supports its credibility and quality [11][13]. Pre-Fulfillment Prescription Period - During the pre-fulfillment prescription period, women can complete telehealth consultations to obtain prescriptions, which will be securely held until pharmacy dispensing begins [5][7]. - Benefits during this period include complimentary telehealth visits and discounts on initial orders and refills of DARE to PLAY™ [8][9]. Company Mission and Vision - Daré Bioscience is dedicated to closing the gap in women's health by providing science-based solutions for various health issues, including sexual health, menopause, and fertility [19][20]. - The company aims to shift the narrative around women's health by offering credible, evidence-backed products that meet the needs of women [20].

Core Insights - DARE to PLAY™ Sildenafil Cream is a groundbreaking female arousal cream designed to enhance genital blood flow and arousal sensations, marking significant progress in women's sexual health [1][2][4] - The product is the first evidence-backed sildenafil cream formulation for women, manufactured under current Good Manufacturing Practice (cGMP) regulations [3][6] - Daré Bioscience aims to address the long-standing gap in women's sexual health solutions, providing a scientifically validated option for women experiencing arousal challenges [5][10] Product Overview - DARE to PLAY™ utilizes sildenafil, the same active ingredient in Viagra®, applied topically to improve genital blood flow without systemic effects [4][6] - The cream is available for prescription in select states, with plans for broader availability in the coming months [7][10] - The product is supported by multiple clinical trials and peer-reviewed research, ensuring its efficacy and safety [9][10] Market Opportunity - An estimated 20 million women in the U.S. face challenges related to genital arousal, highlighting a significant unmet need in the market [10] - The introduction of DARE to PLAY™ provides access to a clinically supported product for this underserved demographic [10] - Daré Bioscience is committed to closing the gap in women's health by advancing science-based solutions across various areas, including sexual health [12][13]

Core Insights - Daré Bioscience is set to launch DARE to PLAY™ Sildenafil Cream by the end of 2025, which is expected to generate near-term revenue through the 503B compounding pathway [1][3][7] - The company reported positive interim results from the Ovaprene® Phase 3 study, supporting continued enrollment and indicating potential for a hormone-free contraceptive option [1][3][7] - Daré is advancing multiple grant-funded programs aimed at women's health, including treatments for HPV and long-acting non-hormonal contraception, with four products expected to be commercially available within the next two years [1][2][8] Financial Highlights - For Q3 2025, Daré reported total revenue of $2.26 million, a significant decrease from $41.69 million in Q3 2024, primarily due to reduced royalty revenue [9][24] - Operating expenses for Q3 2025 were approximately $3.67 million, down from $4.72 million in the same quarter of the previous year, with a notable decrease in R&D expenses by 56% [13][24] - The net loss for Q3 2025 was $3.56 million, compared to a net loss of $4.70 million in Q3 2024, indicating improved financial performance year-over-year [24] Product Pipeline and Development - DARE to RESTORE™ Vaginal Probiotics are targeted for launch in Q1 2026, followed by DARE to RECLAIM™ Monthly Hormone Therapy expected in early 2027, establishing entry into the $4.5 billion compounded hormone therapy market [3][12] - The company is actively pursuing FDA approval for its products while leveraging the 503B pathway for quicker market access [3][12][21] - Ongoing discussions with the FDA regarding endpoint assessments for the Sildenafil Cream Phase 3 studies are in progress, indicating a proactive approach to regulatory compliance [3][21] Grant-Funded Initiatives - The DARE-HPV program is currently funded by an ARPA-H award and NIH grant, focusing on a novel intravaginal therapy for persistent high-risk HPV infections [2][4] - DARE-LARC1 is in preclinical development, fully funded by a foundation grant, aimed at providing long-acting contraceptive solutions [2][4] - DARE-NHC is a preclinical research initiative supported by grant funding to develop a non-hormonal contraceptive product suitable for women in low- and middle-income countries [4]

Core Insights - Daré Bioscience is hosting a webinar on November 17, 2025, to discuss its innovative product DARE to PLAY™, a topical sildenafil cream designed specifically for women [1][2] - DARE to PLAY™ is the first evidence-backed sildenafil cream for women, showing increased genital blood flow within 10 to 15 minutes of application and improvements in arousal sensations [2][3] - The product is expected to be commercially available through a 503B outsourcing facility by the end of 2025, marking a significant advancement in women's sexual health solutions [2][3] Company Overview - Daré Bioscience focuses on addressing gaps in women's health through science-based solutions, with a commitment to rigorous clinical research and development [4][5] - The company aims to provide credible, evidence-based therapies for various women's health issues, including sexual health, menopause, and fertility [4][5] - Daré is a female-led organization recognized for its contributions to innovation and advocacy in women's health, with leadership acknowledged in industry publications [6] Product Details - DARE to PLAY™ is a unique formulation that enhances genital blood flow and arousal response, supported by FDA-reviewed clinical data [2][3] - The product's anticipated launch will be the first time a topical sildenafil formulation manufactured under cGMP requirements is available to healthcare providers [2][3] - The webinar will feature expert clinicians discussing the product's benefits and clinical data, providing an opportunity for participants to join a product alert list [3]

Core Insights - Daré Bioscience is on track to launch DARE to PLAY™ Sildenafil Cream in Q4 2025 through a 503B compounding pathway, with expected product revenue beginning in the same quarter [1][4][6] - Positive interim results from the Ovaprene® Phase 3 study support continued enrollment, highlighting the potential of this hormone-free contraceptive [1][4][6] - The company is advancing multiple grant-funded programs targeting HPV and long-acting contraception, with four commercially available solutions for women anticipated [1][2][4] Financial Highlights - For Q2 2025, Daré reported a total revenue of $(21.2) million, a decrease from $22.4 million in Q2 2024 [19] - General and administrative expenses were $2.4 million, slightly down from $2.5 million year-over-year, while research and development expenses decreased significantly by 71% to $1.4 million [11][19] - The company had approximately $5.0 million in cash and cash equivalents as of June 30, 2025, with a working capital deficit of approximately $12.6 million [11][21] Product Development and Pipeline - DARE to PLAY™ Sildenafil Cream is positioned as a near-term commercial opportunity, with a direct-to-patient campaign launched in collaboration with Rosy Wellness [4][6] - Ovaprene® is being developed as a first-in-category, hormone-free intravaginal contraceptive, with interim pregnancy rates aligning with company expectations [4][6] - The DARE-HPV program is funded by an ARPA-H award and NIH grant, focusing on treating persistent high-risk HPV infections [4][6] Strategic Initiatives - The company is executing a dual-path strategy aimed at unlocking both near-term revenue and long-term value through the commercialization of its products [6] - Discussions with the FDA are ongoing regarding endpoint assessments for the Phase 3 clinical studies of Sildenafil Cream [4][6] - Daré is also targeting the compounded hormone therapy market, estimated at $4.5 billion, with proprietary monthly hormone therapy expected to launch in late 2026 [4][6]